 |
|
|
| |
Artificial intelligence to measure fibrosis change on liver biopsy in MAESTRO-NASH: a Phase 3 52-week serial liver biopsy study in 966 patients with NASH treated with resmetirom or placebo
|
| |
| |
EASL 2023 June 21-24 Vienna
Stephen A. Harrison,1 Rebecca Taub,2
Dominic Labriola,2 Elaine Chng,3
Yayun Ren,3 Dean Tai3
1 Pinnacle Research, San Antonio, TX, USA
2 Madrigal Pharmaceuticals, Conshohocken, PA, USA 3 Histoindex Pte. Ltd., Singapore
EASL 2023 - Primary results from MAESTRO-NASH a pivotal phase 3 52-week serial liver biopsy study in 966 patients with NASH and fibrosis - (06/26/22)
|
| |
|
|
|
|
|
